COCHHealthcare · Medical DevicesThe 3 Wall Street analysts covering Envoy Medical, Inc. hold a median 12-month price target of $20 — +207.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 28 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Envoy Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (80): Smaller than most of the companies we track.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on COCH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +207.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | Lake Street | Maintains | Buy | $2.50 → $25 |
| 6 Oct 2026 | Lake Street | Initiates | Buy | $2.50 |
| 21 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $2.50 → $2.00 |
| 21 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 July 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 27 July 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | $2.00 |
| 15 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $2.50 |
| 15 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Mar 2026 | HC Wainwright & Co. | Initiates | Buy | $2.50 |
| 31 Mar 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 27 May 2025 | Ascendiant Capital | Maintains | Buy | — |
| 21 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 6 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 14 Oct 2024 | Brookline Capital | Initiates | Buy | — |
| 3 Sept 2024 | Ascendiant Capital | Maintains | Buy | — |
| 24 June 2024 | Ascendiant Capital | Initiates | Buy | — |
| 3 Apr 2024 | Lake Street | Maintains | Buy | — |
| 21 Dec 2023 | Northland Capital Markets | Initiates | Outperform | — |
| 28 Nov 2023 | Lake Street | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
COCH appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Envoy Medical, Inc. returned −17.1% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 3% of US stocks
Cheaper than 7% of US stocks
Cheaper than 71% of US stocks
Higher than 8% of US stocks
Higher than 15% of US stocks
Higher than 1% of US stocks
Higher than 2% of US stocks
Higher than 1% of US stocks
Higher than 99% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Envoy Medical, Inc. has a market value of $51.5M and an enterprise value of $32.5M.
Revenue in the twelve months to 30 June 2026: $207K. The latest quarter shrank 34.6% year on year.
Net income over the same four quarters: −$23.4M, a −11304.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$21.7M.
Envoy Medical, Inc. spent $1K on dividends in the twelve months to 30 June 2026.
Trailing P/E: −5.5×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Envoy Medical, Inc. employs 43 people — $5K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Envoy Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Envoy Medical updated the time of its conference call on third-quarter 2026 financial results to 8:00 a.m. ET on Thursday, November 5. The company said results will be released before the market opens.
Why it matters — COCH watchers can note the revised timing for the company's third-quarter results and conference call.
Envoy Medical announced it will report financial results for the third quarter ended September 30, 2026, on Thursday, November 5, 2026. Management will host a conference call at 4:30 p.m. ET that day.
Why it matters — COCH watchers can note the scheduled date and time for the company’s quarterly results and management call.
Envoy Medical announced a 1-for-10 reverse stock split of its outstanding Class A common stock, effective at 12:01 a.m. Eastern Time on October 26, 2026.
Why it matters — COCH watchers may want to note the announced share-structure change and its effective date.
Envoy Medical said its pivotal trial of the investigational fully implanted Acclaim cochlear implant has passed the six-month follow-up milestone, marking halfway through the final stage of data collection. The company said it remains on track to reach the 12-month visit milestone by early Q2 2027 and submit the final clinical PMA module by the end of Q2 2027.
Why it matters — The milestone and stated timeline provide COCH watchers an update on progress in the Acclaim implant's pivotal clinical trial and planned regulatory submission.
Envoy Medical announced it submitted the second of four planned modules in its modular PMA application for the Acclaim cochlear implant to the FDA. The module primarily contained engineering information and follows the first module submitted June 30, 2026.
Why it matters — The submission advances the company's rolling FDA review and its stated goal of completing the final clinical module submission in Q2 2027.
The 3 Wall Street analysts covering Envoy Medical, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Envoy Medical, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Envoy Medical, Inc. 46 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Envoy Medical, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (80 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +207.7% from the last close, and Ticker Nerd's factor model ranks Envoy Medical, Inc. 46 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Envoy Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COCH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $25 over the next 12 months.
Envoy Medical, Inc. returned -17.1% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Envoy Medical Inc Class A Common Stock represents ownership in Envoy Medical, a hearing health company focused on medical technologies for people with hearing loss. The company develops and markets fully implanted hearing solutions, with its current product portfolio centered on the Esteem FI-AMEI, a fully implanted active middle ear implant, and related replacement components.
The most recent item we track (Newsfile Corp, 28 Oct 2026): "Envoy Medical Updates Third Quarter 2026 Earnings Call Time to 8:00 A.M. ET on Thursday, November 5th". Envoy Medical updated the time of its conference call on third-quarter 2026 financial results to 8:00 a.m. ET on Thursday, November 5. The company said results will be released before the market opens.
Envoy Medical Inc Class A Common Stock represents ownership in Envoy Medical, a hearing health company focused on medical technologies for people with hearing loss. The company develops and markets fully implanted hearing solutions, with its current product portfolio centered on the Esteem FI-AMEI, a fully implanted active middle ear implant, and related replacement components. Envoy Medical also has an investigational cochlear implant program under development, reflecting its broader role in the hearing device market. Based in White Bear Lake, Minnesota, the company operates in the healthcare and medical devices space and serves patients and providers seeking alternatives to traditional hearing aids and other hearing technologies. Its business is concentrated in the hearing segment, where it aims to improve usability, access, and quality of life through implantable solutions.
CEO Mr. Brent T. Lucas Esq. · 43 employees · United States · https://www.envoymedical.com
